Covered recipient · General Payments record
GAUTAM BORTHAKUR
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$3,357.33
4 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $3,280.00 | 2 |
| Food and Beverage | $77.33 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,679.99 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $677.34 | 2 |
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GAUTAM BORTHAKUR
NPI 1629177944 · CMS profile ID 346312
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1629177944?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GAUTAM BORTHAKUR, NPI 1629177944, CMS profile ID 346312. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629177944?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). GAUTAM BORTHAKUR, NPI 1629177944, CMS profile ID 346312. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629177944?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- GAUTAM BORTHAKUR, NPI 1629177944, CMS profile ID 346312, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1629177944?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
4 matching records · $3,357.33 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–4 of 4.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,620.00 | 12/06/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658935717 | CMS |
| Novartis Pharmaceuticals Corporation | $59.99 | 12/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658935723 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.34 | 09/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697401041 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $660.00 | 06/15/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697373893 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $481,974.58 | 1 |
| PY2024 | Principal investigator | $79,669.55 | 3 |
| PY2023 | Recipient | $71,592.50 | 1 |
| PY2023 | Principal investigator | $36,848.00 | 3 |
| PY2022 | Principal investigator | $569,901.54 | 33 |
| PY2021 | Principal investigator | $404,764.38 | 36 |
| PY2020 | Recipient | $1,087.58 | 1 |
| PY2020 | Principal investigator | $558,754.27 | 55 |
| PY2019 | Recipient | $103.92 | 2 |
| PY2019 | Principal investigator | $1,118,089.03 | 60 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
56 records in PY2020
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $17,890.50 | 11/16/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | An Open-Label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 719483345 |
| Principal investigator 1 | Incyte Corporation | $14,027.10 | 11/05/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744271043 |
| Principal investigator 1 | Incyte Corporation | $3.06 | 10/08/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302591 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 10/08/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302593 |
| Principal investigator 1 | Incyte Corporation | $70.50 | 10/08/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302595 |
| Principal investigator 1 | Incyte Corporation | $85.50 | 10/08/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302597 |
| Principal investigator 1 | Incyte Corporation | $32.94 | 10/08/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302599 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 10/08/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302603 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $34,628.38 | 09/14/2020 | Non-covered Recipient Entity UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 3 | A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF | No dispute reported | 06/30/2026 | 734917633 |
| Principal investigator 1 | Incyte Corporation | $0.68 | 09/08/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302521 |
| Principal investigator 1 | Incyte Corporation | $19.10 | 09/08/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302523 |
| Principal investigator 1 | Incyte Corporation | $19.00 | 09/08/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302525 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $183,174.74 | 08/25/2020 | Non-covered Recipient Entity UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 3 | A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF | No dispute reported | 06/30/2026 | 734912539 |
| Principal investigator 1 | Otsuka Pharmaceutical Co., Ltd. | $53,750.00 | 08/14/2020 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1, PARALLEL, OPEN-LABEL STUDY OF THE SAFETY AND TOLERABILITY, PHARMACOKINETICS, AND ANTILEUKEMIC ACTIVITY OF ASTX660 AS A SINGLE AGENT AND IN COMBINATION WITH ASTX727 IN SUBJECTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) | No dispute reported | 06/30/2026 | 753030763 |
| Principal investigator 1 | Incyte Corporation | $19.10 | 08/10/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302527 |
| Principal investigator 1 | Incyte Corporation | $2.76 | 08/10/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302529 |
| Principal investigator 1 | Incyte Corporation | $70.50 | 08/10/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302531 |
| Principal investigator 1 | Incyte Corporation | $19.10 | 08/10/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302533 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,248.60 | 08/03/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | An Open-Label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 719483333 |
| Recipient | Amgen Inc. | $1,087.58 | 07/14/2020 | Covered Recipient Physician | An assessment of treatment outcomes in a historical cohort of patients with relapsed or refractory | No dispute reported | 06/30/2026 | 731624407 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,133.46 | 07/09/2020 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS | A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE | No dispute reported | 06/30/2026 | 734914293 |
| Principal investigator 1 | Incyte Corporation | $2.76 | 07/09/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744273605 |
| Principal investigator 1 | Incyte Corporation | $32.94 | 07/09/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744273607 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 07/09/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744273609 |
| Principal investigator 1 | Incyte Corporation | $70.50 | 07/09/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744273611 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 07/09/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744273613 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 07/09/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744273615 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 07/01/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744296149 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,415.53 | 06/18/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | An Open-Label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 719483321 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $36,679.00 | 06/18/2020 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PHASE 1B STUDY OF PTC299 IN RELAPSED/REFRACTORY ACUTE LEUKEMIAS | No dispute reported | 06/30/2026 | 748309233 |
| Principal investigator 1 | Incyte Corporation | $47.75 | 06/08/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744273571 |
| Principal investigator 1 | Incyte Corporation | $54.90 | 06/08/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744273573 |
| Principal investigator 1 | Incyte Corporation | $141.00 | 06/08/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744273575 |
| Principal investigator 1 | Incyte Corporation | $65.88 | 06/08/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744273577 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $95,394.10 | 06/03/2020 | Non-covered Recipient Entity UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | ELTROMBOPAG FOR THE MANAGEMENT OF THROMBOCYTOPENIA ASSOCIATED WITH TYROSINE KINASE THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CML | No dispute reported | 06/30/2026 | 721497239 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 06/01/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744296137 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 05/01/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744296131 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 04/01/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744296127 |
| Principal investigator 1 | Incyte Corporation | $57.00 | 03/09/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744273523 |
| Principal investigator 1 | Incyte Corporation | $2.04 | 03/09/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744273525 |
| Principal investigator 1 | Incyte Corporation | $32.94 | 03/09/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302419 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 03/01/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744296085 |
| Principal investigator 1 | AstraZeneca UK Limited | $2,101.96 | 02/29/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I/II Open-Label Multicentre 2-Part Study to Assess the Safety Tolerability Pharmacokinetics and Efficacy of AZD2811 Nanoparticle as Monotherapy or in Combination in Treatment-Na?ve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy | No dispute reported | 06/30/2026 | 736745427 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $18,249.90 | 02/28/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Maximum Tolerated Dose Study Japan Global expansion | No dispute reported | 06/30/2026 | 736755955 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 02/10/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302407 |
| Principal investigator 1 | Incyte Corporation | $70.50 | 02/10/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302409 |
| Principal investigator 1 | Incyte Corporation | $2.22 | 02/10/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302411 |
| Principal investigator 1 | Incyte Corporation | $28.50 | 02/10/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302413 |
| Principal investigator 1 | Incyte Corporation | $131.20 | 02/10/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302415 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 02/10/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302417 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 02/10/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744302447 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 02/01/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744296081 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $53,380.00 | 02/01/2020 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | PHASE 1B STUDY OF PTC299 IN RELAPSED/REFRACTORY ACUTE LEUKEMIAS | No dispute reported | 06/30/2026 | 748309231 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,862.00 | 01/14/2020 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE | No dispute reported | 06/30/2026 | 734898783 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,870.06 | 01/02/2020 | Non-covered Recipient Entity UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 3 | A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF | No dispute reported | 06/30/2026 | 734899803 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 01/01/2020 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | No dispute reported | 06/30/2026 | 744296077 |